OliX Pharmaceuticals seeks FDA nod for phase 2a trial of OLX10010
OliX Pharmaceuticals, a South Korean pharma company, has submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA) seeking its consent to begin a phase 2a clinical trial for OLX10010 in reducing the recurrence of hypertrophic scars after scar revision surgery. The developer of RNAi therapeutics intends to assess the […]